I know the biotech industry has been very difficult in recent...

I know the biotech industry has been very difficult in recent times, so has the regulator ...but there are things within the control of the company that could be done better.

Have you forgotten that the Board has voted to defer some renumeration until this difficult period is resolved?
You want them to both set everything right, hire and reorganise for succession and to incorporate 'new management ideas' plus protect the company?
Having stalled or frozen renumeration is not going to attract the brightest and best.
Let them get their ducks in a row at an appropriate time.
Protecting the company is number one. They have done this very well.

Given the revenue runway has been spelled out (see @Phaedrus ' post above) let's give them a break.
We only have a few months for this to emerge with final approval. No doubt progress is being made with other elements of this including partnerships which will be contingent on approval.
Patience Grasshopper, patience.